Loading...
 
Toggle Health Problems and D

Breast Cancer not prevented by 1,000 IU of Vitamin D (no surprise) – RCT Aug 2021

A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast

JNCI Cancer Spectrum, Volume 5, Issue 4, August 2021, pkab072, https://doi.org/10.1093/jncics/pkab072
Rita Peila, PhD, Xiaonan Xue, PhD, Jane A Cauley, DrPH, Rowan Chlebowski, MD, PhD, JoAnn E Manson, DrPH, MD, Rami Nassir, PhD, Nazmus Saquib, MBBS, MPH, PhD, Aladdin H Shadyab, PhD, Zhenzhen Zhang, PhD, Sylvia Wassertheil-Smoller, PhD ...
Image

VitaminDWiki

Risk of Ductal Carcinoma
Intervention time = 7 years
Control Group 400 IU + Calcium daily
Placebo Group: allowed to take up to 1,000 IU of vitamin D + Calcium daily
 
This is the first RCT I can recall seeing in which the "placebo" could get more than the control
I have seen RCTs canceled because people were not willing to get no vitamin D
     Henry Lahore, founder of VitaminDWiki


Overview Breast Cancer and Vitamin D

 Download the PDF from VitaminDWiki

Background
The effect of calcium plus vitamin D (CaD) supplementation on risk of ductal carcinoma in situ (DCIS) of the breast, a nonobligate precursor of invasive ductal carcinoma, is not well understood. In this secondary analysis, we examined this association in the Women’s Health Initiative CaD trial over approximately 20 years of follow-up.

Methods
A total of 36 282 cancer-free postmenopausal women (50-79 years) were randomly assigned to daily (d) calcium (1000 mg) plus vitamin D (400 IU) supplementation or to a placebo. Personal supplementation with vitamin D (≤600 IU/d, subsequently raised to 1000 IU/d) and calcium (≤1000 mg/d) was allowed. The intervention phase (median = 7.1 years), was followed by a postintervention phase (additional 13.8 years), which included 86.0% of the surviving women. A total of 595 incident DCIS cases were ascertained. Hazard ratios (HRs) plus 95% confidence intervals (CIs) were calculated.

Results
The intervention group had a lower risk of DCIS throughout follow-up (HR = 0.82, 95% CI = 0.70 to 0.96) and during the postintervention phase (HR = 0.76, 95% CI = 0.61 to 0.94). The group that used CaD personal supplements in combination with the trial intervention had a lower risk of DCIS compared with the trial placebo group that did not use personal supplementation (HR = 0.72, 95% CI = 0.56 to 0.91).

Conclusions
CaD supplementation in postmenopausal women was associated with reduced risk of DCIS, raising the possibility that consistent use of these supplements might provide long-term benefits for the prevention of DCIS.

Title change made April 2022 caused the visitor count to reset.
There have actually been 1085 visitors to this page since it was originally made


Attached files

ID Name Comment Uploaded Size Downloads
16160 BC intervention.jpg admin 31 Aug, 2021 20:40 77.98 Kb 229
16159 BC 400 1000.pdf PDF 2021 admin 31 Aug, 2021 20:39 1.26 Mb 160